

IN THE UNITED STATES PATENT OFFICE

In re: Klimko et al.

Serial No: NYA

Filed: August 21, 1997

For: USE OF CLOPROSTENOL
AND FLUPROSTENOL
ANALOGUES TO TREAT
GLAUCOMA AND OCULAR
HYPERTENSION

CERTIFICATE OF MAILING
BY EXPRESS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EM367125014US in an envelope addressed to: Assistant Commissioner for Patents, Box Patent Applications, Washington, D.C. 20231 on this date:

Date: 8-21-97
Name: Dawn Fedyniak
Dawn Fedyniak

mt
#2
3/05/98

INFORMATION DISCLOSURE STATEMENT UNDER
37 CFR §§1.56, 1.97 AND 1.98

Assistant Commissioner of Patents
BOX PATENT APPLICATIONS
Washington, DC 20231

Sir:

Pursuant to the duty of disclosure under 37 CFR §§1.56, 1.97 and 1.98, Applicants submit the attached PTO Form 1449 and copies of thirty-three (33) references in connection with the above-referenced application being filed herewith.

Most of these references have been submitted and considered by the Examiner in the prosecution of prior, related applications. References which may not have been previously submitted or considered are identified on the attached PTO form 1449 as follows:

AB, AF, AI-AL, AO, AS, BL-BN, and CL


Applicants request that the references listed in the accompanying PTO Form 1449 be considered during prosecution of the above-referenced application, and that

these references appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

ALCON LABORATORIES, INC.

Date: 8-21-97

By: 
Barry L. Copeland
Reg. No. 34,801

Patent Department (Q-148)
Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, Texas 76134
(817) 551-4322

Atty. Docket No. 1407B